Bausch + Lomb Announces Second-Quarter 2022 Results

/PRNewswire/ -- Bausch + Lomb Corporation, (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company", "we" or "our"), a leading global eye health company dedicated to...

Related Keywords

Norway ,United States ,New Jersey ,Israel ,China ,Ireland ,Canada ,Cyprus ,America ,Canadian ,Novaliq Gmb ,Josephc Papa ,Prnewswire Bausch ,Revenue Service ,Instagram ,Linkedin ,Twitter ,Lomb Corporation ,Company Registration Statement On Form ,Clearside Biomedical Inc ,Ophthalmic Pharmaceuticals Segment ,Canada Revenue Agency ,Facebook ,Bausch Lomb Incorporated ,Bausch Health Companies Inc ,Drug Administration ,Exchange Commission ,Ophthalmic Pharmaceuticals ,Revenues Grew ,Strong Performance ,Vision Care ,Surgical Segments ,Year Revenue ,Custom Soft Contact Lenses ,New Drug Application ,Hydration Plus Multi Purpose Solution ,Sanoculi Minimally Invasive Micro Sclerostomy ,Months Ended ,Contact Lens ,Per Share ,Forward Looking Statements ,Event Dial In ,North America ,Access Code ,Bausch Health Companies ,Canadian Securities Administrators ,Securities Act ,Registration Statement ,Internal Revenue Service ,Net Income ,Like Adjusted ,Lomb Incorporated ,Consolidated Statements ,Six Months Ended June ,Adjusted Net ,Adjusted Earnings Per Share ,Months Ended June ,Organic Revenue Growth ,Organic Revenue ,Three Months ,Six Months ,Clearside Biomedical ,Novaliq Gmbh ,Bausch Lomb Corporation ,